The abstract is read at the publisher; the summary is JClub's.
Replicating RNA therapeutics (including self-amplifying RNA and defective interfering RNAs) can generate more copies in cells, potentially improving strength and duration versus non-replicating RNAs.
- Why it matters: RNA medicines for infections, cancer, and inherited diseases need clearer guidance on trade-offs in immune effects, dosing, delivery, and manufacturing across replicating versus non-replicating designs.
- What they did: This review compares mechanisms, design and delivery approaches, including lipid nanoparticles (LNPs) and polymer-based systems, and discusses long-studied DI RNAs as an emerging antiviral class.
- The result: The comparison suggests replicating strategies may better support potency, persistence, and immune triggering, while DI RNAs are being developed with broad antiviral activity and an emerging preclinical safety profile.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.